Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...

"Importantly, islatravir dosed at a daily dose of 0.25 mg did not adversely ... inferior to either BIC/FTC/TAF or oral ART, providing a daily, single-tablet alternative to those who require ...

once-daily DOR/ISL (100mg/0.25mg) in adults with HIV-1 infection that has been virologically suppressed on BIC/FTC/TAF (50mg/200mg/25mg). The primary efficacy endpoint was the percentage of ...

Gilead Sciences, Inc. today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses ...

The ALLIANCE trial is the first randomized clinical trial of TAF- vs TDF-based regimens in ... mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg) is indicated as a complete regimen for the ...

Antiviral therapy with a once-daily single-tablet regimen of doravirine plus islatravir ... Switch to DOR/ISL (100/0.25 mg) QD from BIC/FTC/TAF: A blinded phase III study in adults with HIV-1.

For those seeking the ultimate LTE tablet experience in 2025, this article highlights the top five options, each offering cutting-edge cellular connectivity and the latest technology. Designed ...

The Murena Pixel Tablet doesn’t include Google’s speaker dock but comes with a steeper $549 price tag. The Murena Pixel Tablet doesn’t include Google’s speaker dock but comes with a ...

If you see inaccuracies in our content, please report the mistake via this form. Drawing with a tablet has many benefits, such as portability, chargeability, and limitless visual effects.

Whether you're looking for an Amazon, Android, or Apple slate, here's what to consider, along with recommendations for the top tablets we've tested. I’m one of PCMag’s mobile analysts.